Diatech Pharmacogenetics http://diatechpharmacogenetics.com/rss.php?lng=en Diatech Pharmacogenetics : News en Diatech Pharmacogenetics Bronze Sponsor at AMP Global 2017 http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017 24.03.2017

Diatech Pharmacogenetics will be Bronze Sponsor at AMP GLOBAL 2017



http://diatechpharmacogenetics.com/en/893/diatech-pharmacogenetics-bronze-sponsor-at-amp-global-2017]]>
Leonid EU opportunities Italian success - A revolutionary diagnostic device for lung cancer http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer 21.11.2016 PROGRAM

10:00 Welcome to Diatech!
Hall, 2° flor

11:00 Presentation of the results of the project LEONID
Auditorium, 2° flor

Welcome greetings

Fabio Biondi - Diatech Pharmacogenetics  President

Luca Ceriscioli - President of Regione Marche Mariangela Siler DG research and innovation in Health, Ministry of Health

11:30 Regional policies in the health field - Manuela Bora  Productive Activities of the Marche Region

11:50 Italian companies in European and national programs for R&I - Nicoletta Amodio Manager Research and Innovation, Confindustria

12:10 The history and the results of the project LEONID - Maura Menghi Scientific Director Diatech Pharmacogenetics

12:30 LEONID clinical study: presentation of preliminary results - Paola Ulivi Settore Biomarcatori e Medicina Personalizzata- Diagnostica molecolare III livello, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS Meldola

12:45 Myriapod® Lung Fusion Genes in the clinical practice  - Gabriella Fontanini Dipartimento di Patologia Medica Molecolare e di Area Critica, University of Pisa

13:00 Networking lunch, 2° flor

 

 

 



http://diatechpharmacogenetics.com/en/861/leonid-eu-opportunities-italian-success-a-revolutionary-diagnostic-device-for-lung-cancer]]>
Diatech and Inno-Train Diagnostik partecipate at the DGPhato congress http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress 19.05.2016 Diatech partecipate with Inno-Train Diagnostik our Germany distributor exclusive for the Easy line at the DGPhato Congress in Berlin from may 19th to 21st.
 
Come to visit us!
 
 


http://diatechpharmacogenetics.com/en/846/diatech-and-inno-train-diagnostik-partecipate-at-the-dgphato-congress]]>
Diatech will be at States General Of Health Research http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research 26.04.2016 We will participate at the event "States General Of Health Research", on 27 and 28 April at the Auditorium Massimo, Rome.
For information visit the event website.
The speech of AD Oliva Alberti of Diatech Pharmacogenetics will be April 28 during "Health and Smart Technology. New tools for biomedical research: challenges and opportunities".
See the complete program.

 



http://diatechpharmacogenetics.com/en/834/diatech-will-be-at-states-general-of-health-research]]>
Diatech will be at the Workshop and School on Cancer Development and Complexity http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity 23.04.2016 Diatech will partecipate at the "Lake Como Workshop and School  on Cancer Development and Complexity" May 24 – 27, 2016 – Villa del Grumello, Como, ITALY

Keynote Speakers

For more information visit the website .

 

 



http://diatechpharmacogenetics.com/en/833/diatech-will-be-at-the-workshop-and-school-on-cancer-development-and-complexity]]>
Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment 27.10.2015 SAN DIEGO, Calif., Oct. 27, 2015 — Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics. The MassARRAY Dx PLUS assays improve upon existing methods on the market, enabling highly multiplexed screening of actionable targets in a single assay, thereby dramatically reducing cost and turnaround time for testing laboratories.

MassARRAY Dx PLUS assays will provide parallel analysis of the most frequently observed and actionable mutations in colon, lung, or melanoma tumors. Labs can rapidly test for the most critical mutations in KRAS, NRAS, BRAF, EGFR, and ALK genes to drive better patient treatment outcomes.

Clinical practice guidelines, such as those set forth by the European Society of Medical Oncology, necessitate screening mutations in oncogenes such as EGFR and/or KRAS for targeted treatment. As personalized treatment has evolved with the discovery of new biomarkers, as well as the advent of novel cancer drugs, such as tyrosine kinase inhibitors, the number of actionable mutations has expanded. However, the lack of a cost-effective, practical method for screening in parallel has complicated the ease of introducing new mutations into clinical testing.

For the compleate news plese go here.



http://diatechpharmacogenetics.com/en/827/agena-bioscience-and-diatech-pharmacogenetics-announce-plan-to-launch-actionable-targeted-ce-ivd-marked-oncology-assays-for-colon-lung-and-melanoma-treatment]]>
Diatech Pharmacogenetics obtained by the European Union a founding of Euro 2 million in Horizon 2020 http://diatechpharmacogenetics.com/en/762/diatech-pharmacogenetics-obtained-by-the-european-union-a-founding-of-euro-2-million-in-horizon-2020 Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/762/diatech-pharmacogenetics-obtained-by-the-european-union-a-founding-of-euro-2-million-in-horizon-2020 http://diatechpharmacogenetics.com/en/762/diatech-pharmacogenetics-obtained-by-the-european-union-a-founding-of-euro-2-million-in-horizon-2020 27.03.2015

The Group Diatech, leader in Italy  of pharmacogenetics and pharmacogenomics sectors , obtained by the European Union funding of approximately Euro 2 million in Horizon 2020 with the research project LEONID (Lung Cancer Genes Fusion: a new Diagnostic Device).
The main objective of the project is to develop an innovative diagnostic test that allows the analysis of some tumor markers decisive in the choice of treatment of lung cancer. Compared to traditional methods, this molecular test permits to get much more informations, speeding up diagnosis and significantly reducing costs. The use of this diagnostic test certificate by the European Union associated with a software for data analysis allow to obtain standardized results and avoid the personal interpretation of the information . In this way the reduction of the human in the analysis also will significantly reduce the error rate in the reporting, thereby favoring the choice of the most appropriate therapy for patients suffering from lung cancer.
LEONID is the result of the synergy between Diatech Pharmacogenetics , the absolute leader in Italy in pharmacogenetics and customization of care with a market share of 70%, BiMind and GeneticLab, companies owned by the Group.

For more information please contact marketing[at]diatechpgx.com

 



http://diatechpharmacogenetics.com/en/762/diatech-pharmacogenetics-obtained-by-the-european-union-a-founding-of-euro-2-million-in-horizon-2020]]>
Diatech Pharmacogenetics is pleased to announce the launch of the kit myriapod Lung status http://diatechpharmacogenetics.com/en/712/diatech-pharmacogenetics-is-pleased-to-announce-the-launch-of-the-kit-myriapod-lung-status Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/712/diatech-pharmacogenetics-is-pleased-to-announce-the-launch-of-the-kit-myriapod-lung-status http://diatechpharmacogenetics.com/en/712/diatech-pharmacogenetics-is-pleased-to-announce-the-launch-of-the-kit-myriapod-lung-status 26.06.2014
The kit Myriapod® Lung status (SQ011, CE-IVD) is used to detect nucleotide variants in parallel 307, relative to the genes EGFR, KRAS, BRAF, PIK3CA, NRAS, ALK, ERBB2, DDR2, MAP2K1 and RET by MALDI-TOF Mass Spectrometry associated with the technology Single Base Extension.

The panel consists of 8 multiplex reactions, each of which needs only 5 ng of DNA extracted from fresh tissue, frozen or paraffin, or cells.

With the kit provided all reagents and consumables necessary for the execution of 120 tests, divided into 10 independent analytical sessions, each for 10 clinical samples and 2 controls the reaction, respectively positive (wild-type human genomic DNA for all variants investigated) and negative, which are also included in the product.

The system allows to genotype automatically and completely reproducible, samples with an accuracy ≥ 99.7% and a sensitivity that can drop to below 5% of mutated allele.

For further informations please write to marketing[at]diatechpharmacogenetics.com



http://diatechpharmacogenetics.com/en/712/diatech-pharmacogenetics-is-pleased-to-announce-the-launch-of-the-kit-myriapod-lung-status]]>
Physiomics enters the personalized medicine market. Anticipated new collaboration with Diatech Pharmacogenetics http://diatechpharmacogenetics.com/en/708/physiomics-enters-the-personalized-medicine-market-anticipated-new-collaboration-with-diatech-pharmacogenetics Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/708/physiomics-enters-the-personalized-medicine-market-anticipated-new-collaboration-with-diatech-pharmacogenetics http://diatechpharmacogenetics.com/en/708/physiomics-enters-the-personalized-medicine-market-anticipated-new-collaboration-with-diatech-pharmacogenetics 12.06.2014 Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a Heads of Terms agreement with Diatech Pharmacogenetics srl (“Diatech”) to negotiate a Collaboration Agreement. Under the terms of the anticipated Collaboration Agreement Physiomics and Diatech will develop an innovative in-silico platform to personalize cancer patient treatment.
This anticipated new in-silico platform will combine pharmacological information related to cancer drugs with genomic and physiological information about the patient, to predict which treatments and regimens are likely to lead to an increase in survival. The platform will initially be used to support physicians to make the best choice of available treatment options for patients. Ultimately, the software could be further developed to choose the right patient groups for clinical trials of new drugs.
The parties anticipate signing a full collaboration agreement within 6 months and a further announcement will be made at that time if it is executed.
Diatech is the market leader for cancer Pharmacogenetics in Italy with a 80% market share into the CE IVD segment. They would provide the necessary clinical calibration via an existing network of cancer centres. If completed, the directors believe the collaboration would provide a direct route to market for Italy and potentially other Diatech clients in Europe, where the software developed could be sold in combination with Diatech’s kits.

Read the complete press release



http://diatechpharmacogenetics.com/en/708/physiomics-enters-the-personalized-medicine-market-anticipated-new-collaboration-with-diatech-pharmacogenetics]]>
Diatech Pharmacogenetics at the European at Human Genetics Conference, May 31st - June 3rd, 2014 http://diatechpharmacogenetics.com/en/703/diatech-pharmacogenetics-at-the-european-at-human-genetics-conference-may-31st-june-3rd-2014 Diatech Pharmacogenetics srl http://diatechpharmacogenetics.com/en/703/diatech-pharmacogenetics-at-the-european-at-human-genetics-conference-may-31st-june-3rd-2014 http://diatechpharmacogenetics.com/en/703/diatech-pharmacogenetics-at-the-european-at-human-genetics-conference-may-31st-june-3rd-2014 28.05.2014 Join us at the stand number 348 with Diatech LabLine and Nanostring Technologies

The European HumanGenetics Conference that will be held in Milan from 31st May to 3rd June 2014 is now in its 47th year. It is a forum for all workers in human and medical genetics to review advances and develop research collaborations. The conference has become one of the premier events in the field of human genetics with over 3.000 delegates, more than 215 oral presentations, 13 workshops, 8 educational sessions, and over 150 exhibiting companies. The ESHG conference is where the latest developments in human genetics are discussed, and where professionals from all parts of human genetics meet.



http://diatechpharmacogenetics.com/en/703/diatech-pharmacogenetics-at-the-european-at-human-genetics-conference-may-31st-june-3rd-2014]]>